LONG -TERM EFFICACY AND REAL -WORLD OUTCOMES OF TERIPARATIDE IN SEVERE OSTEOPOROSIS
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Sprache: | Englisch |
| Veröffentlicht: |
Zenodo
2026
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901198027620352 |
|---|---|
| author | Shifana S.*1, Dr. Brijith G. Mohan*2 |
| author_facet | Shifana S.*1, Dr. Brijith G. Mohan*2 |
| contents | <p><span>Teriparatide is a synthetic fragment of human parathyroid hormone (PTH), represents a crucial class of anabolic agents in the management of severe osteoporosis. As the first approved therapy to directly stimulate new bone formation, it has shown robust efficacy in reducing fracture risk and increasing Bone Mineral Density (BMD) in pivotal short-term trials. However, in the long term real-world controlled studies evaluating its sustained impact on clinical outcomes particularly fractures and Health-Related Quality of Life (HRQoL) have been scarce. This review synthesizes the established mechanisms and clinical trial data for teriparatide and provides a critical analysis of its long-term effectiveness based on a recent 10-year follow-up study in patients with established osteoporosis. The evidence suggests that short-term teriparatide treatment, </span><span>followed by subsequent bone-specific agents can achieve a </span><span>sustained reduction in fracture prevalence over a decade to levels comparable to those of the general population. Conversely, despite the decrease in fractures, health-related quality of life (HRQoL) continues to be problematic in this severely impacted patient population, underscoring the significant disabling effects of established osteoporosis.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18885557 |
| institution | Zenodo |
| language | eng |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | LONG -TERM EFFICACY AND REAL -WORLD OUTCOMES OF TERIPARATIDE IN SEVERE OSTEOPOROSIS Shifana S.*1, Dr. Brijith G. Mohan*2 <p><span>Teriparatide is a synthetic fragment of human parathyroid hormone (PTH), represents a crucial class of anabolic agents in the management of severe osteoporosis. As the first approved therapy to directly stimulate new bone formation, it has shown robust efficacy in reducing fracture risk and increasing Bone Mineral Density (BMD) in pivotal short-term trials. However, in the long term real-world controlled studies evaluating its sustained impact on clinical outcomes particularly fractures and Health-Related Quality of Life (HRQoL) have been scarce. This review synthesizes the established mechanisms and clinical trial data for teriparatide and provides a critical analysis of its long-term effectiveness based on a recent 10-year follow-up study in patients with established osteoporosis. The evidence suggests that short-term teriparatide treatment, </span><span>followed by subsequent bone-specific agents can achieve a </span><span>sustained reduction in fracture prevalence over a decade to levels comparable to those of the general population. Conversely, despite the decrease in fractures, health-related quality of life (HRQoL) continues to be problematic in this severely impacted patient population, underscoring the significant disabling effects of established osteoporosis.</span></p> |
| title | LONG -TERM EFFICACY AND REAL -WORLD OUTCOMES OF TERIPARATIDE IN SEVERE OSTEOPOROSIS |
| url | https://doi.org/10.5281/zenodo.18885557 |